BioNTech sees up to 17 billion eur in vaccine revenue this year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pfizer (PFE) Asks FDA to Amend EUA and Include Booster for Everyone 18+, Analyst Sees Good Chances for Winning Approval and Upgrades BioNTech (BNTX) to Buy
November 11, 2021 9:01 AM ESTYesterday, Germany recommended only the Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NYSE: BNTX) for under the 30s as it causes fewer heart inflammations in younger people than the Moderna (NASDAQ: MRNA).
The committee also recommended pregnant women receive only the BioNTech/Pfizer vaccine.
In the meantime, two... More
BioNTech (BNTX) PT Lowered to $289 at Goldman Sachs
November 11, 2021 7:19 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $289.00 (from $433.00) while maintaining a Neutral rating.
The analyst commented, "While vaccine marketplace trends continue to provide tailwinds for mRNA-vaccine manufacturers, more hesitant management commentary around the endemic phase... More
